RxDoctor Payments Data

Gary Golduber, MD

Cardiovascular Disease · Rego Park, NYNPI 1467635599

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 54 payments — averaging $32.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$364
  • Medtronic$354
  • E.r. Squibb & Sons, L.L.C.$228
  • Philips North America LLC$214
  • Pfizer$196
  • Actelion Pharmaceuticals US, Inc.$95
  • plus $320 from 10 others

What the payments were for

  • Food & beverage$1,67595%
  • Education$955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,770 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$392,532
Medicare patients
813
Services billed
4,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban855$711,396
FarxigaDapagliflozin Propanediol227$178,030
JardianceEmpagliflozin152$156,041
MultaqDronedarone Hcl98$93,296
EntrestoSacubitril/Valsartan57$54,684
XareltoRivaroxaban66$46,054
Repatha SureclickEvolocumab77$42,116
BrilintaTicagrelor63$37,130
CrestorRosuvastatin Calcium79$30,051
Praluent PenAlirocumab45$27,645
Metoprolol Succinate1,698$18,189
Ranolazine ErRanolazine445$16,696
DapagliflozinDapagliflozin Propanediol25$15,313
EdarbyclorAzilsartan Med/Chlorthalidone43$15,151
PlavixClopidogrel Bisulfate34$12,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lipitor$196$723,361870 claims
NovartisEntresto, Diovan$18$62,48970 claims
Esperion Therapeutics, Inc.Nexlizet$17$5,67511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →